Literature DB >> 17537846

General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines.

Hans J Kueng1, Victoria M Leb, Daniela Haiderer, Graça Raposo, Clotilde Thery, Sophia V Derdak, Klaus G Schmetterer, Alina Neunkirchner, Christian Sillaber, Brian Seed, Winfried F Pickl.   

Abstract

Viral particles preferentially incorporate extra- and intracellular constituents of host cell lipid rafts, a phenomenon central to pseudotyping. Based on this mechanism, we have developed a system for the predictable decoration of enveloped viruses with functionally active cytokines that circumvents the need to modify viral proteins themselves. Human interleukin-2 (hIL-2), hIL-4, human granulocyte-macrophage colony-stimulating factor (hGM-CSF), and murine IL-2 (mIL-2) were used as model cytokines and fused at their C terminus to the glycosylphosphatidylinositol (GPI) acceptor sequence of human Fcgamma receptor III (CD16b). We show here that genetically modified cytokines are all well expressed on 293 producer cells. However, only molecules equipped with GPI anchors but not those linked to transmembrane/intracellular regions of type I membrane proteins are efficiently targeted to lipid rafts and consequently to virus-like particles (VLP) induced by Moloney murine leukemia virus Gag-Pol. hIL-4::GPI and hGM-CSF::GPI coexpressed on VLP were found to differentiate monocytes towards dendritic cells. Apart from myeloid-committed cell types, VLP-bound cytokines also act efficiently on lymphocytes. hIL-2::GPI strongly costimulated T-cell receptor (TCR)/CD3 dependent T-cell activation in vitro and mIL-2::GPI-coactivated antigen-specific T cells in vivo. On a molar basis, the functional activity of VLP-bound hIL-2::GPI was found to be comparable to that of soluble hIL-2. VLP decorated with hIL-2::GPI and coexpressing a TCR/CD3 ligand have an IL-2-specific activity of 5 x 10(4) units/mg protein. Virus particles decorated with lipid-modified cytokines might help to improve viral strains for vaccination purposes, the propagation of factor-dependent cell types, as well as gene transfer by viral systems in the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537846      PMCID: PMC1951353          DOI: 10.1128/JVI.00682-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  82 in total

1.  Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells.

Authors:  J M Curtsinger; C S Schmidt; A Mondino; D C Lins; R M Kedl; M K Jenkins; M F Mescher
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

2.  Influenza viruses select ordered lipid domains during budding from the plasma membrane.

Authors:  P Scheiffele; A Rietveld; T Wilk; K Simons
Journal:  J Biol Chem       Date:  1999-01-22       Impact factor: 5.157

3.  Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes.

Authors:  W F Pickl; O Majdic; P Kohl; J Stöckl; E Riedl; C Scheinecker; C Bello-Fernandez; W Knapp
Journal:  J Immunol       Date:  1996-11-01       Impact factor: 5.422

4.  Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12.

Authors:  F Cavallo; P Signorelli; M Giovarelli; P Musiani; A Modesti; M J Brunda; M P Colombo; G Forni
Journal:  J Natl Cancer Inst       Date:  1997-07-16       Impact factor: 13.506

5.  Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor.

Authors:  H P Kiem; R G Andrews; J Morris; L Peterson; S Heyward; J M Allen; J E Rasko; J Potter; A D Miller
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

6.  Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA).

Authors:  Rabindranath Chakrabarti; Yigang Chang; Keli Song; Gerald J Prud'homme
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

7.  Recombinant interleukin 4 promotes the growth of human T cells.

Authors:  H Spits; H Yssel; Y Takebe; N Arai; T Yokota; F Lee; K Arai; J Banchereau; J E de Vries
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

8.  Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses.

Authors:  S C Meuer; M Hauer; P Kurz; K H Meyer zum Büschenfelde; H Köhler
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

9.  Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

Authors:  M B Atkins; M J Robertson; M Gordon; M T Lotze; M DeCoste; J S DuBois; J Ritz; A B Sandler; H D Edington; P D Garzone; J W Mier; C M Canning; L Battiato; H Tahara; M L Sherman
Journal:  Clin Cancer Res       Date:  1997-03       Impact factor: 12.531

10.  Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes.

Authors:  D Unutmaz; V N KewalRamani; S Marmon; D R Littman
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  16 in total

Review 1.  Membrane vesicles as conveyors of immune responses.

Authors:  Clotilde Théry; Matias Ostrowski; Elodie Segura
Journal:  Nat Rev Immunol       Date:  2009-06-05       Impact factor: 53.106

2.  Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages.

Authors:  Irena Kadiu; Prabagaran Narayanasamy; Prasanta K Dash; Wei Zhang; Howard E Gendelman
Journal:  J Immunol       Date:  2012-06-18       Impact factor: 5.422

Review 3.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

4.  Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptor-ligand interactions.

Authors:  Hans J Kueng; Calin Manta; Daniela Haiderer; Victoria M Leb; Klaus G Schmetterer; Alina Neunkirchner; Ruth A Byrne; Clemens Scheinecker; Peter Steinberger; Brian Seed; Winfried F Pickl
Journal:  FASEB J       Date:  2010-01-07       Impact factor: 5.191

5.  Comparison of drug and cell-based delivery: engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models.

Authors:  Linda N Liu; Gang Wang; Kyle Hendricks; Keunmyoung Lee; Ernst Bohnlein; Uwe Junker; Joseph D Mosca
Journal:  Stem Cells Transl Med       Date:  2013-04-16       Impact factor: 6.940

6.  Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule.

Authors:  Steven Froelich; Leslie Ziegler; Katie Stroup; Pin Wang
Journal:  Biotechnol Bioeng       Date:  2009-09-01       Impact factor: 4.530

7.  A novel method to incorporate bioactive cytokines as adjuvants on the surface of virus particles.

Authors:  Yufang Yang; David Leggat; Andrew Herbert; Paul C Roberts; Roys S Sundick
Journal:  J Interferon Cytokine Res       Date:  2009-01       Impact factor: 2.607

Review 8.  Gene and virotherapy for hematological malignancies.

Authors:  Evidio Domingo-Musibay; Masato Yamamoto
Journal:  Int J Hematol       Date:  2016-06-11       Impact factor: 2.490

9.  T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells.

Authors:  Judith Leitner; Werner Kuschei; Katharina Grabmeier-Pfistershammer; Ramona Woitek; Ernst Kriehuber; Otto Majdic; Gerhard Zlabinger; Winfried F Pickl; Peter Steinberger
Journal:  J Immunol Methods       Date:  2010-09-19       Impact factor: 2.303

Review 10.  Gammaretroviral vectors: biology, technology and application.

Authors:  Tobias Maetzig; Melanie Galla; Christopher Baum; Axel Schambach
Journal:  Viruses       Date:  2011-06-03       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.